DB15804ExperimentalGene Therapies
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of... This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
- Also known as
- Covid-19 Synthetic Minigene Vaccine · Lentiviral Minigene Vaccine · LV-SMENP
- Code names
- LV-SMENP Vaccine
What you can answer from here — as of March 06, 2025
Which companies are running trials of LV-SMENP Vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account